Medivir Gets $45M for North American Royalties on Xerese
By Cormac Sheridan
Thursday, June 30, 2011
Adopting the old adage that a bird in the hand is worth two in the bush, Medivir AB is forgoing a future revenue stream from North American sales of its cold sore product Xerese in return for an immediate payment of $45 million from its partner Meda AB.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.